Treatment Sequencing and Line of Therapy for Biologics and JAK Inhibitors in Patients With Rheumatoid Arthritis: Implications for Design and Uptake of New Drugs and Predictive Biomarker Diagnostics

Documenti analoghi

• Neutrophil Activation Markers and Rheumatoid Arthritis Treatment Response to the JAK1/2 Inhibitor Baricitinib
  di: Runa Kuley, et al.
  Pubblicazione: (2024)
• Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug
  di: Fenglong Xie, et al.
  Pubblicazione: (2026)
• Survival in Immune Checkpoint Inhibitor–Treated Patients With Rheumatoid Arthritis and Non–Small Cell Lung Cancer: An Observational Cohort Study
  di: Deanna P. Jannat‐Khah, et al.
  Pubblicazione: (2025)
• Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries
  di: Romain Aymon, et al.
  Pubblicazione: (2025)
• Changes in the Workforce Characteristics of Providers Who Care for Adult Patients With Rheumatologic and Musculoskeletal Disease in the United States
  di: Melissa L. Mannion, et al.
  Pubblicazione: (2024)